Treeline Biosciences goes public via $460M reverse acquisition of Standard BioTools
What's the deal? Standard BioTools (NASDAQ: LAB) and Treeline Biosciences have entered a definitive all-stock agreement that amounts to a reverse acquisition: privately held Treeline gains a Nasdaq listing through the deal, and pre-merger Treeline stockholders are expected to own approximately 84% of the combined company versus roughly 16% for Standard BioTools shareholders. The transaction values Standard BioTools at its net cash delivered at closing plus $10 million — an estimated $460 million. The combined company will operate under the Treeline Biosciences name and trade on Nasdaq under the ticker "TRLN."
The deal brings roughly $450M in net cash from Standard BioTools to the combined entity, which expects more than $900M in pro-forma cash at closing — enough runway to fund operations into 2029. Treeline had previously raised approximately $1.2B from life sciences investors. The transaction is structured to be tax-free to both sets of shareholders and is expected to close in the second half of 2026.
Treeline co-founder and chief executive officer Josh BilenkerDealroom has a profile for this one. Try Dealroom → will lead the combined company. Bilenker previously founded and led Loxo Oncology through three FDA-approved medicines and its $8 billion acquisition by Eli LillyDealroom has a profile for this one. Try Dealroom →; co-founder Jeff EngelmanDealroom has a profile for this one. Try Dealroom → will serve as CSO.
Why now? Founded in 2021, Treeline has moved fast. It already has three programmes in Phase 1 clinical trials targeting molecular pathways in oncology, with a fourth planned to enter the clinic in 2026. Multiple interim data readouts are expected starting in 2027, with three more programmes set to begin clinical testing in 2027 and 2028 across oncology, neurology, and immunology.
Standard BioTools, meanwhile, conducted a strategic review and concluded that combining with Treeline was the best way to maximise shareholder value. "Deploying our capital behind this team and pipeline gives our stockholders exposure to a catalyst-rich portfolio with significant potential for value creation," said Michael Egholm, the company's chief executive officer. Treeline does not intend to operate Standard BioTools' Mass Cytometry and Microfluidics businesses, which are being explored for divestiture; shareholders also receive a contingent value right tied to those legacy assets and up to $50 million in earnouts from Illumina's prior acquisition of Standard BioTools' SomaLogic business.
What could go wrong? Treeline's pipeline — spanning small molecule inhibitors, protein degraders, and targeted therapy antibody-drug conjugates — is still early-stage. None of its programmes have moved beyond Phase 1, and clinical data won't start arriving until 2027. Drug development timelines are notoriously unpredictable, and negative trial results could erode the combined company's value quickly. There's also execution risk in integrating a Nasdaq-listed tools company with a private biotech while maintaining momentum on multiple clinical programmes.
The signal: This deal reflects a broader trend of cash-rich public companies being used in reverse-merger-style transactions to give well-funded private biotechs a faster path to public markets. Rather than pursuing a traditional IPO — which remains choppy for early-stage biotech — Treeline gains a public listing and a significant cash infusion in one move. With over $900M in the bank and seven programmes expected in the clinic by 2028, Treeline is betting it can build a diversified precision-medicines platform at scale — if the science holds up.
Read more: Treeline Biosciences · Standard BioTools
